Short answer
Stoke Therapeutics, Inc. (STOK) filed an 8-K current report with the SEC on August 3, 2026 reporting Item 8.01 (Other Events). Stoke authorized up to $200 million in at-the-market common-stock sales through Cantor Fitzgerald.
Stoke Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Stoke authorized up to $200 million in at-the-market common-stock sales through Cantor Fitzgerald
- Potential equity issuance creates shareholder dilution and provides additional financing flexibility
- Prospectus supplement filed August 3, 2026 under the company’s Form S-3ASR shelf registration
- Sales may occur at market prices, allowing Stoke to raise capital opportunistically rather than through one transaction
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Stoke Therapeutics, Inc. 8-K filings
Get the next STOK 8-K as it lands
Follow STOK for push alerts, or ask the research agent what this filing means.